We are live on
!
Find out more
Mitsubishi UFJ Asset Management Portfolio holdings
AUM
$180B
1-Year Est. Return
37.51%
This Fund
S&P 500
This Quarter
Est. Return
+11.07%
1 Year Est. Return
+37.51%
3 Year Est. Return
+115.4%
5 Year Est. Return
+142.39%
10 Year Est. Return
+552.78%
AUM
$25.2B
AUM Growth
+$4.86B
(+24%)
Cap. Flow
+$2.83B
Cap. Flow
% of AUM
11.26%
Top 10 Holdings %
Top 10 Hldgs %
25.97%
Holding
1,178
New
57
Increased
860
Reduced
151
Closed
43
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$186M |
| 2 |
Microsoft
MSFT
|
+$175M |
| 3 |
Amazon
AMZN
|
+$113M |
| 4 |
Tesla
TSLA
|
+$67.9M |
| 5 |
Meta Platforms (Facebook)
META
|
+$65.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Global REIT ETF
REET
|
+$19.4M |
| 2 |
JD.com
JD
|
+$18.2M |
| 3 |
Ambarella
AMBA
|
+$12.2M |
| 4 |
BLD
TopBuild
BLD
|
+$11.4M |
| 5 |
Teladoc Health
TDOC
|
+$11M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 26.5% |
| 2 | Consumer Discretionary | 12.51% |
| 3 | Healthcare | 12.26% |
| 4 | Financials | 11.24% |
| 5 | Communication Services | 9.19% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1001
Fate Therapeutics
FATE
$322M
| $315K | ﹤0.01% |
5,230
+1,119
| +27% | +$63.4K |
|
|
MRUS
1002
DELISTED
Merus
MRUS
| $314K | ﹤0.01% |
10,163
-1,659
| -14% | -$46.9K |
|
1003
Ultragenyx Pharmaceutical
RARE
$2.64B
| $309K | ﹤0.01% |
3,667
+922
| +34% | +$75K |
|
|
UHT
1004
Universal Health Realty Income Trust
UHT
$576M
| $309K | ﹤0.01% |
5,156
+493
| +11% | +$28.7K |
|
1005
Precigen
PGEN
$2.51B
| $306K | ﹤0.01% |
76,904
+29,751
| +63% | +$128K |
|
|
FOLD
1006
DELISTED
Amicus Therapeutics
FOLD
| $305K | ﹤0.01% |
25,186
-8,955
| -26% | -$99.8K |
|
1007
Immatics
IMTX
$1.33B
| $304K | ﹤0.01% |
23,634
-4,954
| -17% | -$61.9K |
|
1008
Arcturus Therapeutics
ARCT
$200M
| $301K | ﹤0.01% |
7,611
-2,790
| -27% | -$114K |
|
|
CYBE
1009
DELISTED
Cyberoptics Corp
CYBE
| $301K | ﹤0.01% |
6,375
-6,989
| -52% | -$292K |
|
1010
Maravai LifeSciences
MRVI
$904M
| $300K | ﹤0.01% |
7,552
+1,761
| +30% | +$71.3K |
|
1011
ProQR Therapeutics
PRQR
$255M
| $300K | ﹤0.01% |
37,113
-10,542
| -22% | -$80.3K |
|
1012
Paymentus
PAY
$4.91B
| $299K | ﹤0.01% |
+8,799
| New | +$243K |
|
1013
Fulcrum Therapeutics
FULC
$286M
| $298K | ﹤0.01% |
+16,742
| New | +$332K |
|
|
XXII
1014
22nd Century Group
XXII
$1.5M
| – | – |
0
| – | – |
|
1015
ACI Worldwide
ACIW
$5.34B
| $293K | ﹤0.01% |
8,390
-472
| -5% | -$15.1K |
|
|
PAYA
1016
DELISTED
Paya Holdings Inc. Class A Common Stock
PAYA
| $289K | ﹤0.01% |
41,375
+9,140
| +28% | +$74.2K |
|
1017
Iovance Biotherapeutics
IOVA
$2.9B
| $288K | ﹤0.01% |
15,098
-3,753
| -20% | -$82.6K |
|
1018
Repay Holdings
RPAY
$317M
| $287K | ﹤0.01% |
14,700
+215
| +1% | +$4.22K |
|
1019
Arrowhead Research
ARWR
$12.5B
| $284K | ﹤0.01% |
4,065
-263
| -6% | -$18.1K |
|
1020
Blackbaud
BLKB
$2.09B
| $284K | ﹤0.01% |
3,573
-1,045
| -23% | -$80.7K |
|
1021
4D Molecular Therapeutics
FDMT
$582M
| $284K | ﹤0.01% |
+12,538
| New | +$307K |
|
|
ADAP
1022
DELISTED
Adaptimmune Therapeutics
ADAP
| $281K | ﹤0.01% |
69,140
+8,292
| +14% | +$37.7K |
|
|
BFS
1023
Saul Centers
BFS
$839M
| $279K | ﹤0.01% |
5,198
+628
| +14% | +$31.2K |
|
|
BLUE
1024
DELISTED
bluebird bio
BLUE
| $279K | ﹤0.01% |
1,318
+488
| +59% | +$115K |
|
|
CLLS
1025
Cellectis
CLLS
$278M
| $277K | ﹤0.01% |
31,607
+11,858
| +60% | +$117K |
|
Similar funds
VGA
Mitsubishi UFJ Asset Management's Q4 2021 Portfolio in Review
As of Q4 2021, Mitsubishi UFJ Asset Management held 1,178 positions worth $25.2B, up 24% from $20.3B the previous quarter. Its ten largest holdings account for 26% of the portfolio.
Mitsubishi UFJ Asset Management deployed $2.83B of net new capital in Q4 2021, opening 57 new positions and adding to 860 existing holdings. Its largest new stake was Doximity: 162,400 shares worth $8.37M.
By sector, the portfolio is most concentrated in Technology at 27% of assets, up from 25% a quarter earlier, followed by Consumer Discretionary and Healthcare.
On the sell side, the largest reduction was iShares Global REIT ETF, an estimated $19.4M trimmed.
- Mitsubishi UFJ Asset Management's largest Q4 2021 buy was Doximity: 162,400 shares worth $8.37M.
- Mitsubishi UFJ Asset Management added most to Apple in Q4 2021, an estimated $186M increase.
- Mitsubishi UFJ Asset Management's biggest Q4 2021 reduction was iShares Global REIT ETF, cutting an estimated $19.4M.
- Mitsubishi UFJ Asset Management fully exited Beyond Meat in Q4 2021, selling an estimated $10.7M.
- Mitsubishi UFJ Asset Management's ten largest holdings make up 26% of its $25.2B portfolio in Q4 2021.
- Mitsubishi UFJ Asset Management opened 57 new positions and closed 43 in Q4 2021.
- Mitsubishi UFJ Asset Management's portfolio value rose 24% quarter-over-quarter to $25.2B.
Based on Mitsubishi UFJ Asset Management's 13F filing for Q4 2021, filed 7 Feb 2022.